Showing 271-280 of 8690 results for "".
How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaJournal Club: How Physicians Can Use the New AD Guidelines in Practice
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/how-physicians-can-use-the-new-ad-guidelines-in-practice/24094/In this second part of the inaugural edition of Practical Dermatology's® Atopic Dermatitis (AD) Journal Club, Derek Chu, MD, a key architect of new guidelines for AD management and care, talks with Peter Lio, MD, about his vision for how to make these guidelines easy-to-use and practical for dermatoNoah Worcester 2024: Dr. Bridges on Practice Management
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bridges-practice-management/24580/Alina Bridges, DO, FAAD, summarizes her lecture on practice management and coding at the 2024 Noah Worcester Dermatological Society meeting.Journal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Noah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentThe Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.DermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.